Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $0.91 and traded as high as $0.96. Brainstorm Cell Therapeutics shares last traded at $0.9137, with a volume of 723 shares traded.

Brainstorm Cell Therapeutics Price Performance

The stock has a market capitalization of $13.54 million, a P/E ratio of -0.28 and a beta of 0.28. The stock’s fifty day moving average is $0.99 and its two-hundred day moving average is $0.91.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Analysts expect that Brainstorm Cell Therapeutics Inc. will post -3.01 EPS for the current year.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc is a biotechnology company developing cell-based therapies for neurodegenerative diseases. The company’s proprietary NurOwn platform uses a patient’s own bone marrow-derived mesenchymal stem cells, which are expanded and induced to secrete neurotrophic factors and other proteins intended to support the survival and function of nerve cells.

BrainStorm’s lead candidate, NurOwn, has primarily been studied as a potential treatment for amyotrophic lateral sclerosis (ALS).